06:47:39 Europe / Stockholm
Svenska | English

Observe Medical

Share price & Turnover

Share price change and turnover during the day of this press release

Calendar

2024-08-26 Quarterly Report 2024-Q2
2024-05-27 Ex-date Ordinary Dividend OBSRV 0.00 NOK
2024-05-24 Annual General meeting
2024-03-13 Year-end Report 2023
2023-11-22 Extra General Meeting 2023
2023-08-25 Quarterly Report 2023-Q2
2023-05-30 Ex-date Ordinary Dividend OBSRV 0.00 NOK
2023-05-26 Annual General meeting
2023-02-17 Year-end Report 2022
2022-11-03 Quarterly Report 2022-Q3
2022-08-25 Quarterly Report 2022-Q2
2022-06-03 Annual General meeting
2022-06-03 Quarterly Report 2022-Q1
2022-06-03 Ex-date Ordinary Dividend OBSRV 0.00 NOK
2022-03-29 Year-end Report 2021
2022-02-04 Extra General Meeting 2022
2021-11-03 Quarterly Report 2021-Q3
2021-08-20 Quarterly Report 2021-Q2
2021-05-25 Ex-date Ordinary Dividend OBSRV 0.00 NOK
2021-05-21 Annual General meeting
2021-05-12 Quarterly Report 2021-Q1
2021-02-23 Year-end Report 2020
2020-11-03 Quarterly Report 2020-Q3
2020-08-18 Quarterly Report 2020-Q2
2020-07-01 Ex-date Ordinary Dividend OBSRV 0.00 NOK
2020-06-30 Annual General meeting
2020-06-16 Extra General Meeting 2020
2020-05-12 Quarterly Report 2020-Q1
2020-02-25 Year-end Report 2019

Description

CountryNorway
ListOAX Equities
SectorHealth care
IndustryMedical technology
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo, Norge.
Observe Medical ASA - Disclosure of voting rights at the Annual General meeting
2024-05-23 14:07:47

Oslo, 23 May 2024: In connection with the annual general meeting of Observe Medical ASA (the "Company") to be held on 24 May 2024 (the "AGM"), Terje Bakken, chairman of the board of directors of the Company, has received proxies without voting instructions for 24,286,193 shares or 12.24% of the total shares and voting rights in the Company. The proxies are only valid at the AGM.

In addition, Terje Bakken represents Ingerø Reiten Investment Company AS at the board of directors of the Company, who holds 37,384,437 shares or 19.61% of the total shares and voting rights in the Company.

Hence, following the receipt of the proxy, Terje Bakken controls 31.85% of the total shares and voting rights in the Company at the AGM.

This information is subject to the disclosure requirements pursuant to section 4-2 of the Norwegian Securities Trading Act.

Source Cision
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

An email has been sent to the given address. To login please click "Login" in that email to verify your account

Companies

Press releases